or cystic fibrosis is recessive, or diabetes or many, and it takes up to 20 generations for recessive mutations to express themselves. so we're talking about eons of time for expression of genetic disease--that's the second thing. the third thing is if the man's got plutonium in his testicles--and every male in the northern hemisphere has a tiny load in his gonad--it's from weapons testing days, and plutonium is still falling out. and the man is cremated, the smoke goes up the chimney with the plutonium, so you can breathe it in, another man can, and it's ad infinitum because plutonium has a half-life of 24,400 years and lasts for a long time. but the other thing is that the body thinks plutonium is iron--it's an iron analogue--so it's stored in the liver, where it causes liver cancer. it's stored in the bone marrow to cause--to produce hemoglobin in the red blood cells, but it causes leukemia or bone cancer. it crosses the placenta into the developing embryo--which lets nothing through it, incidentally, except plutonium and a few other nasties. it's stored in the testicle, too. so it

his 12-year-old granddaughter has cystic fibrosis. several businesses have made do imaginations.runs 20 miles a day. he expects his whole journey will take 14 months and he's hoping to raise $500,000. >> wow, and document it for him social media involved? >> there is some of that, and people in teach review he goes are helping him to run. >> good to see you. welcome back. you were missed. >> reporter: thank you, i missed you, too. >> what a story here. a nine-year-old girl kills her gun instructor with an automatic uzi, and that girl was at the gun range with her parents. we'll look at what the laws are in that situations and whether there should be stricter regulations. >> new orleans is dealing with an guns and crimes. how is the city responding to the rise in violence there? >> reporter: well, tony, right now there is some 50 additional state troopers. how long they'll be here. how long they'll stay remains to be scene. this is not just a neighborhood issue where a few neighborhoods were having problems. it's become a citywide issue. you're familiar with bourbon street. famed

his 12-year-old granddaughter has cystic fibrosis. several businesses have made donations. he runs 20 miles a day and he's been on the road for 80 days. he expects the journey will take 14 months. he has had support from so many local. >> it's he has to be doing social campaign. >> he has facebook page and you can call it the social media. >> are you back later? >> i am. >> thank you. people who live near a massive oil stands deposit in canada are worried about a cancer cluster in their community. we have reports from fort chiperyan. in alberta. >> one of dozens to contract cancer in recent years. breast cancer in her case. now she's in remission but some of her friends haven't been so lucky. she and others are worried that their beloved hometown is a cancer hot spot. >> we live here, and we see our neighbors, our friends being diagnosed. i think in the back of our minds we sort of say, i wonder who is next. >> at the local clinic nursing staff say most of their patients live in fear of their health. >> x-rays, ct scan, mri. they want all those tests to be done just to be o

the lead product is a drug for treating pulmonary fibrosis, which is a fatal disease to scar the lungs> news of the tie-up between the companies sent shares in chugai lower as they are no longer pursuing the buyout of the japanese company that already owns 60% of the shares. >>> and burger king is in talks to form a new publicly openlist business in canada. the tax rate in canada is less than what is seen in the u.s. a burger king tim horton's merger would create the third largest fast food restaurant chain. >>> now, coming up here on the show, britain's ambassador to the u.s. says the agencies are close to identifying the killer of the u.s. journalist james foley. we'll be talking iraq just after the break. we've also got more with regards to u.s. housing and we'll talk about what's coming up stateside, too. stay with us here on "worldwide exchange." [ woman ] the cadillac summer collection is here. ♪ ♪ [ male announcer ] during the cadillac summer's best event, lease this 2014 ats for around $299 a month. hurry in -- this exceptional offer ends soon. ♪ >>> welcome back. i'm louisa bo

talking to rbc great biotech analyst, he said it exceed all expectations and showed reversal of fibrosis, which is a scaring of the liver, that's what they were looking for to see this disease reversed. >> how do you pick a company? >> when you have a binary outcome like this, i think it's too dangerous, unless you have tremendous expertise, for us, we like being in a biotech space. i can't wake up with failed free phase 3 drug trial. >> dan, you are trading biotech. >> when it first gapped up, i knew smart edge funds buying it in the after market. i'm not certain that will go on. we thought the results back then were so positive. now you have a move back to that level. you probably see profit taking here. these drugs have to come to market. you have to realize those sorts of sales. i don't touch anything up 50% on the day. >> good to see you, thanks for all the biotech movers. thanks for those names as well, coming up on "fast money" the hot social media player that could be the next takeover target. yes, it is a business of selfies, plus big name hedge funds, one commodity play that's

this spring they came out with a pulmonary fibrosis drug that showed dramatic possibilities.his compound which addresses a market of 100,000 americans will most likely receive fda approval by the end of the year because this drug can actually stop an illness from being fatal. there is nothing else out there that's been able to arrest this horrible progressive disease. roche will presumably have the market all to itself with this purchase. they have a small pulmonary business with its own sales force and this drug will help the company instantly diversify away from its core oncology business. this drug was too good for the company not to be snapped up for a big pharma concern. if you listened to me, you caught an 87% gain. please ring the register tomorrow morning. it has lost more than $1 billion in the last nine years. it has an amazingly overstretched valuation. how about the fact that there were apparently other equally growth challenged buyers out there who forced roche to reach so high to get it. which brings me back to the new definition of bolt-on. typically on a confe

it's called i h ee eed ideaopat fibrosis. it's a devastating fatal disease.nts typically will die two to three years after diagnosis. and intermune has developed this important medicine, give new hope to patients and that's why we are so excited about this opportunity. it really fits into what we are doing, focusing on innovation, true medical differentiation for patients. >> and maybe you can tell us a little bit about the drug in the eu and canada and its approval pathway in the u.s. now approval is expected in the u.s. maybe you can tell us about the opportunity here. >> yeah, the opportunity is very important, as he said. this is a terrible disease. it affects at least 100,000 patients, probably more. the patients die very quickly. they have very bad time breathing. and today there's not one drug approved at all. so it's as if a cancer patient would be told today. you have cancer, and you have no therapy. very soon in america, we hope to change that answer to say you have ipf, but now you have a new medicine that can really help you. so we're very, very e

this works on fibrosis and inflammation. but this is really the main focus.his is what drug companies want. they want unmet medical need. they want chronic therapies. they want a lot of pricing power. analysts say this could bring in you know $80,000 per patient per year. that's how much this could cost the united states. obviously it's a lot less in europe. but what's interesting is we're talking so much about inversions, and we've been seeing that more than anywhere in health care. but this is not one of those deals. roche obviously is a swiss company. >> they have an advantage though. >> they have a tax advantage over the company that they've bought. absolutely. >> oh, that's absolutely true -- >> potentially -- >> they can afford that asset because it's worth more to them than an american company buying -- >> right. >> they could pay more -- >> but -- >> so we're losing -- >> by taxes here. roche isn't buying it because of the taxes. >> but it's easier for them -- what's cool about this deal people say return to the big pharma buying biotech for growth an

foxx findings were consistent with progressive massive fibrosis, another term for complicated black lung. however, mr. foxx treating physicians also were concerned about the possibility of lung cancer. they removed a five-centimeter mess from his right upper lung, but thankfully was not cancer but the local pathologist did not diagnose like long, even though he said it contained numerous deposits. mr. foxx was to working and realizing to get out of the dust and filed a claim for federal black lung benefits. 's claim was approved. elk run it was represent by experienced attorneys from the law firm jackson and kelly hired to expert pathologists who both found that the samples of mr. fox's lung tissue actually were consistent with complicated black lung. lawyers and judges for my with black lung litigation know that pathology is the gold standard and that helped runs to expert pathology reports met the requirements for benefit from the act. in other words, elk run knew that mr. foxx qualified but elk runs attorneys not only withheld those two reports but also used the discredited opinion of

we are already doing selection to avoid cystic fibrosis.f you had the capability of altering genetics, there are 60% to 70% of people who say they would enhance the physicality of children if they could with genetic engineering. so this is where this is going. of course there is a lot of angst with it. but the idea that we can stop is absurd. it's not like there is one little technology that is causing all of these weird things. this is happening across a broad technology front. it is not one genie who needed help out of a bottle. it is hundreds everyday. look at the way the internet is going. this is big stuff that is happening and here is what is really going on. this was 2500 years ago. he said, -- that is really the charge that we have to take for us and our children. how do we deal with these incredibly challenging and difficult technologies that are really altering our sense of who we are and what we are and what life is all about. that is where the situation is heading. [applause] >> i would like to give each speaker an opportunity t

but he has cystic fibrosis. a life threatening lung and digestive disease.is airway. and medication before eating anything. >> i have to do these therapies. i have to take my medication every day if i want to survivor. >> gunner was diagnosed at two. >> when you get that news you think the worst. >> boomer was just traded to the jets. he realized that football gave him a national platform. >> figuring i'm in the media capital of the world and how i could use that to leverage who i am to raise money and awareness of the disease. >> that year they launched the boomer esiason foundation. >> we support hospital development. >> in two decades they have raised more than $100 million. >> it's not easy. it's pain staking and time consuming. but sitting next to me i have a passion for it. where the reward was that what if tnew car smelledit card and the freedom of the open road? a card that gave you that "i'm 16 and just got my first car" feeling. presenting the buypower card from capital one. redeem earnings toward part or even all of a new chevrolet, buick, gmc or

we are already doing selection to avoid cystic fibrosis. if you could act to late -- if you had the capability of altering genetics, there are 60% to 70% of people who say they would enhance the physicality of children if they could with genetic engineering. so this is where this is going. of course there is a lot of angst with it. but the idea that we can stop is absurd. it's not like there is one little technology that is causing all of these weird things. this is happening across a broad technology front. it is not one genie who needed help out of a bottle. it is hundreds everyday. look at the way the internet is going. this is big stuff that is happening and here is what is really going on. years ago.00 said, -- that is really the charge that we have to take for us and our children. how do we deal with these incredibly challenging and difficult technologies that are really altering our sense of who we are and what we are and thank you. one another befo we open it up to the audience. i do want to ask one question. we presume that we know

. >> they were referring to pulmonary fibrosis. >> a portfolio in a product.these companies they have one drug. allergen, botox, multiple uses. this drug is not just for this terrible disease that is five years progressive and people die from it. so this is one that the fda, whatever they see a fatal disease, they're going to approve if it works. this will get approval, could be $1 billion a year drug, ancillary things. the roche coo came out and said -- took my breath away -- this is a full-on acquisition. when i heard that, it men $200 million. this is $8.3 bolt on. this is where you have to be. now, ironically, because i think janet yellen's doing a very good job. >> here it comes. >> they came out and said that it's the -- this is where the -- this is where the overstretched valuations are, in the meantime if you're roach, you're sitting there with an oncology franchise, trying to expand. here is intermune, a drug, could be life saving, 100,000 suffers in this country, another 100,000 overseas, buy for $8 been, a new product line, you have a sales force fo

groups that have done that like cyst stick f cystic fibrosis, that's why they succeeded in getting the products on to the market because they have the patients ready and they have genotype. and i'm very interesting in the drug manufacturing. there's a lot of innovation in drug manufacturing. we're having a big meeting in a few weeks about this. right now we have drug shortages that are afflicting the hospitals across this country. we are buy many of our drugs from other countries. and if something would happen, won't be able to get the drugs anymore. hostilities, natural disaster, whatever. and thirdly, that's another thing faced by developers. they have to continue to try to scale up their manufacturing and it's very much like the clinical trial system. very outdated. very cumbersome. there's now the technologies available to do these continuous manufacturing and make things that could be made in the united states. they wouldn't have to be all over the place. it's environmentally friendly and it's the wave of the future and how drugs should be made. where they're needed. so i think th

that's right, roche is paying $74 a share for intermune and it gets a drug for interpathic pulmonary fibrosis, affecting about 100,000 people in the u.s. and 100,000 people in europe and there's nothing on the market to treat it. it's approved in canada and europe but not yet in the u.s. analysts expect that this year. they think this could be a billion-dollar-plus drug in peak annual revenue and the ceo of roche told us today which is the drug that made intermune a fit for roche. >> it's, of course, the perfect strategic fit. it's a focus on medical differentiati differentiation. it fits very well to our preliminary portfolio. >> now, when you see biotech deals like these, there's a lot of speculation that more will follow. you've seen record deals in health care, but primarily driven by the tax inversions. now they think we may have a return to big pharma. isi group did a survey of investors today and has a list of names they're looking at, like puma biotech, biomarin, intercept, vertex. we'll see if any of those are next on the docket. >> thanks, meg, for bringing that to us. by the way, n

the cystic fibrosis foundation was noted and the prostate cancer foundation. the melanoma research alliance is out there. a multitude of these groups. what i think the system can learn from these groups and what we have studied is that they are one-stop-shopping in terms of understanding what science do we know and what don't we know and what do we need to be getting prepared for. where's the puck going to go? and how do you bring the patient into the center of all of that? so a couple of points that i wanted to make sure i talked about at the topline is the sacredness of this 'innovation ecosystem and the real need for that stability to come and then the putting the patient at the center of it. i want to mack sure that as you do your work, we're making sure that happens. thank you. >> first of all, i want to thank you for convening this important committee and i want to thank congress for their work. actually, recently, through the reauthorization of the user fee act we had -- [ audio difficulty ] >> i'm trying. we had a mechanism that was sponsored by friend